Streetbeat News

Equity Actions

BDX

Analysts have recently provided mixed reviews on Becton Dickinson (NYSE:BDX), with 4 somewhat bullish ratings in the past three months. The average 12-month price target has been lowered to $276.00 from $297.00, indicating a 7.07% decrease. Analysts from Raymond James and Piper Sandler have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Becton Dickinson is a major medical surgical products manufacturer, with BD Medical, BD Life Sciences, and BD Interventional as its business segments. The company's financials show solid revenue growth but below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 6:00 pm

SBRA

Sabra Health Care REIT (NASDAQ:SBRA) has received varied analyst ratings over the past three months, with 5 analysts offering ratings ranging from bullish to indifferent. The average 12-month price target has increased to $15.8, up 12.86% from the previous target of $14.00. Analysts from Mizuho, Stifel, Wells Fargo, and BMO Capital have raised their price targets and ratings, reflecting positive sentiment towards SBRA's stock. Sabra Health Care REIT, a healthcare facility REIT, has shown a revenue growth of 14.82% as of September 30, 2023, but struggles with below industry average net margin, ROE, and ROA, while maintaining a prudent debt-to-equity ratio of 0.82.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 6:00 pm

ABT

Analysts have mixed views on Abbott Laboratories (NYSE:ABT), with recent ratings ranging from bullish to indifferent. Over the last three months, there have been 5 ratings with 4 somewhat bullish and 1 indifferent. The average 12-month price target is $115.6, down 3.18% from the previous $119.40. Analysts from Raymond James and Wells Fargo have raised their price targets, while Morgan Stanley lowered theirs. Abbott's market cap is above industry average, but it saw a revenue decline of -2.56% as of September 30, 2023. The company has a high net margin of 14.16% but a lower than average ROE of 3.85%. Its debt-to-equity ratio is conservative at 0.41.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 6:00 pm

FLEX

NXT

Flex Ltd. (NASDAQ:FLEX) shares rose after announcing the completion of the spin-off of its remaining interest in Nextracker Inc. (NASDAQ:NXT) to Flex shareholders. Flex shareholders received approximately 0.17 shares of Nextracker Class A common stock for each Flex share held, with a total of 74,432,619 Nextracker shares distributed. Flex no longer holds Nextracker stock. Flex shares traded higher on heavy volume, more than double the 100-day average.

Portfolio Pulse from Erica Kollmann

January 03, 2024 | 5:53 pm

T

TMUS

VZ

KeyBanc analyst Brandon Nispel upgraded Verizon Communications Inc (VZ) with a price target of $45, citing tailwinds and attractive valuation. Verizon's market cap is over $163 billion, with an enterprise value of $339 billion, higher than AT&T's (T) and T-Mobile's (TMUS). Verizon has higher quality cash flows and a TTM Free Cash Flow/Share of $3.25, compared to AT&T's $2.76. Over the past year, VZ stock is up 4.03%, while T is down 1.77%. Despite this, AT&T may appear more attractively valued on current parameters, and is ranked as the top telecom pick for 2024 by BofA Securities and is on Citi's buy-rated stocks list.

Portfolio Pulse from Surbhi Jain

January 03, 2024 | 5:52 pm

TRV

Travelers Companies Inc. (NYSE:TRV) stock increased by 6.28% over the past month and by 3.21% over the past year. Currently, TRV has a P/E ratio of 20.67, which is higher than the Insurance industry's aggregate P/E ratio of 19.37, potentially indicating that the stock might be overvalued. Investors are advised to use the P/E ratio cautiously and consider it alongside other financial metrics and industry trends.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:45 pm

CI

ELV

HCSG

HUM

UNH

Cigna Group is in advanced talks to sell its Medicare Advantage business to Health Care Service Corp for $3B-$4B. The deal would expand HCSC's Medicare business and reach. Cigna's previous attempt to acquire Humana was met with lukewarm investor response. Cigna plans $10B in stock buybacks and smaller 'bolt-on' acquisitions. Cigna has 599,000 Medicare Advantage members, trailing UnitedHealth and Humana.

Portfolio Pulse from Vandana Singh

January 03, 2024 | 5:35 pm

CRGY

Crescent Energy (NYSE:CRGY) has received mixed analyst ratings over the past quarter, with 1 bullish, 2 somewhat bullish, and 1 indifferent rating. The average 12-month price target for CRGY has increased by 1.56% to $16.25, with a high estimate of $19.00 and a low estimate of $14.00. Analysts from Mizuho, Raymond James, Evercore ISI Group, and Wells Fargo have provided recent evaluations, with Wells Fargo raising its price target from $16.00 to $19.00. Crescent Energy's financial performance shows challenges, with a revenue decline of -25.73%, a net margin of -8.23%, an ROE of -3.46%, an ROA of -0.8%, and a high debt-to-equity ratio of 1.25.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:01 pm

SCHW

Charles Schwab (NYSE:SCHW) has been analyzed by 9 analysts, showing a shift towards a more cautious stance with a decrease in the average price target by 2.47%. The average 12-month price target is $71.33, with a high of $85.00 and a low of $55.00. Analysts' actions include maintaining, raising, and lowering ratings and price targets. Schwab's financial performance shows a revenue decline of -16.25%, a high net margin of 22.08%, an exceptional ROE of 3.6%, but a low ROA of 0.21% and a high debt-to-equity ratio of 2.24.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:00 pm

MTDR

Matador Resources (NYSE:MTDR) received mixed analyst ratings over the past quarter, with 4 analysts offering opinions ranging from bullish to bearish. The average 12-month price target is $74.75, down 3.76% from the previous $77.67. Analyst actions include both raised and lowered price targets, reflecting changes in market conditions and company performance. Matador Resources is an independent energy company with a focus on oil and natural gas resources in the United States. Despite a market cap below industry averages and a recent -8.16% decline in revenue growth, the company has a high net margin of 34.15%, an ROE of 7.47%, and an ROA of 3.62%, with a conservative debt-to-equity ratio of 0.6.

Portfolio Pulse from Benzinga Insights

January 03, 2024 | 5:00 pm